Our infectious disease pipeline is dedicated to developing broad-spectrum, small-molecule antiviral drugs. Target indications include epidemic diseases such as coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).